Artiva Biotherapeutics (NASDAQ:ARTV) Stock Rating Lowered by Wedbush

Artiva Biotherapeutics (NASDAQ:ARTV) was downgraded by equities research analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Tuesday, Marketbeat reports. They presently have a $4.00 price target on the stock. Wedbush‘s price objective points to a potential downside of 6.32% from the company’s previous close.

Several other research firms have also recently issued reports on ARTV. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 target price on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. HC Wainwright restated a “buy” rating on shares of Artiva Biotherapeutics in a research note on Friday, October 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Monday, October 19th. Finally, Wall Street Zen upgraded shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $30.00.

Artiva Biotherapeutics Stock Down 30.7%

ARTV traded down $1.89 during midday trading on Tuesday, hitting $4.27. 8,646,973 shares of the company traded hands, compared to its average volume of 436,190. The firm has a market capitalization of $208.76 million, a PE ratio of -1.29 and a beta of 2.40. The company’s 50-day moving average is $8.80 and its 200 day moving average is $7.96. Artiva Biotherapeutics has a 52 week low of $2.96 and a 52 week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.63). On average, sell-side analysts predict that Artiva Biotherapeutics will post -2.62 earnings per share for the current fiscal year.

Insider Transactions at Artiva Biotherapeutics

In other news, insider Christopher Horan sold 10,340 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $6.84, for a total value of $70,725.60. Following the transaction, the insider owned 312,744 shares in the company, valued at $2,139,168.96. This represents a 3.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Fred Aslan sold 61,696 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $6.84, for a total transaction of $422,000.64. Following the completion of the transaction, the chief executive officer owned 1,543,069 shares in the company, valued at $10,554,591.96. This trade represents a 3.84% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 137,048 shares of company stock worth $1,086,167. 1.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several institutional investors have recently made changes to their positions in the business. 5AM Venture Management LLC bought a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $22,827,049. Blue Owl Capital Holdings LP bought a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $8,483,000. BlackRock Inc. bought a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $6,739,000. Nantahala Capital Management LLC purchased a new stake in Artiva Biotherapeutics in the 2nd quarter worth approximately $2,910,000. Finally, Alyeska Investment Group L.P. increased its holdings in Artiva Biotherapeutics by 173.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after acquiring an additional 173,615 shares in the last quarter.

Artiva Biotherapeutics News Roundup

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Artiva reported approximately $319.1 million in cash, cash equivalents and investments as of September 30, 2026. The company is evaluating strategic alternatives and has hired Leerink Partners as a financial adviser, potentially creating value through a partnership, asset sale or other transaction. Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK
• Neutral Sentiment: Trading in ARTV was temporarily halted for pending news before the strategic update was released, reflecting the material nature of the announcement. Trading Halt Report
• Negative Sentiment: Artiva halted further development of AlloNK, including its planned Phase 3 rheumatoid arthritis trial, after longer-term data showed that the treatment’s clinical response was not durable enough to meet the company’s requirements. This eliminates the program that was central to the company’s investment thesis. Artiva Biotherapeutics Ends AlloNK Program, Explores Strategic Options
• Negative Sentiment: The company disclosed two recent Grade 5 events, or patient deaths, in the program. One involved leukoencephalopathy assessed as likely related to fludarabine toxicity, while the other was assessed as unrelated to study treatment. The safety events increase regulatory and investor concerns even though the company said one death was not treatment-related. Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%
• Negative Sentiment: Artiva plans to reduce its workforce by approximately 94%, signaling a near-term restructuring and a substantial reduction in internal development capacity. Analysts responded with downgrades: Needham moved from Buy to Hold, while Wedbush cut its rating from Outperform to Neutral and set a $4.00 price target. Artiva Biotherapeutics Discontinues Development of AlloNK

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.